Description | GSK2983559 (compound 3, RIP2 kinase inhibitor 1, RIPK2-IN-1) is a potent inhibitor of receptor interacting protein 2 (RIP2) kinase with good kinase specificity. | |
---|---|---|
Targets |
| |
In vitro | In a screen against nonkinase targets (Eurofins, 104 receptor and ion channel binding assays and 35 enzyme and cell-based assays), GSK2983559 is highly selective, inhibiting only melatonin receptor MT3 at a concentration under 10 μM.[1]. | |
In vivo | Administration of GSK2983559 at the 7.5 and 145 mg/kg b.i.d doses exhibits efficacy similar to that of prednisolone as measured by summed colon scores in a murine 2,4,6-trinitrobenzenesulfonic acid (TNBS) induced colitis model.[1]. |